FDA LISTING INC: EXPERIENCED ADVISORS FOR FULL-SERVICE FDA REGISTRATION & COMPLIANCE
+1 212 444 8202
FDA Ophthalmic Monograph M018 outlines conditions that may apply to over-the-counter ophthalmic drug products marketed in the United States, including permitted active ingredients, concentration ranges, labeling, directions, warnings, and related compliance requirements.
Ophthalmic products are OTC drug products intended for topical use in or around the eye. FDA Monograph M018 covers certain ophthalmic products, including eye drops, artificial tears, lubricating eye drops, redness-relief drops, eye washes, hypertonicity products, and similar ophthalmic dosage forms.
For brand owners, importers, private-label companies, and manufacturers, key compliance considerations include the active ingredient and concentration, intended use, dosage form, sterility, Drug Facts labeling, required warnings, directions for use, and FDA drug establishment registration and drug-listing requirements.
FDA Monograph M018 may apply to artificial tears, lubricating eye drops, dry-eye products, redness-relief drops, eye washes, eye-irritation relief products, ophthalmic astringents, hypertonicity eye drops, and similar topical ophthalmic products. The product format alone does not determine whether a product fits the monograph. Also review the active ingredient, concentration, intended use, dosage form, sterility, directions for use, warning statements, and labeling claims. A product’s claims should match the applicable active ingredient conditions and the finished formulation.
OTC ophthalmic products should be sterile in final packaged form and use appropriate container-closure and tamper-evident packaging controls. Sterility and packaging requirements are critical considerations for eye drops, eye washes, and other ophthalmic drug products.
Products marketed to treat glaucoma, eye infections, allergic conjunctivitis, chronic dry eye disease, cataracts, contact-lens discomfort, eye pain, eye injuries, vision changes, or other eye conditions may fall under a different FDA regulatory framework. An ophthalmic product should not use claims that exceed its applicable M018 conditions.
| Active Ingredient | Concentration Range | Common Product Terms |
|---|---|---|
| Carboxymethylcellulose sodium | 0.2% to 2.5% | Artificial tears, dry-eye drops, lubricating eye drops |
| Hypromellose | 0.2% to 2.5% | Lubricating eye drops, artificial tears |
| Hydroxyethyl cellulose | 0.2% to 2.5% | Artificial tears, ophthalmic lubricant |
| Polyvinyl alcohol | 0.1% to 4% | Lubricating eye drops, dry-eye relief drops |
| Povidone | 0.1% to 2% | Artificial tears, lubricating eye drops |
| Glycerin | 0.2% to 1% | Lubricating eye drops, dry-eye product |
| Polyethylene glycol 400 | 0.2% to 1% | Artificial tears, eye lubricant |
| Propylene glycol | 0.2% to 1% | Lubricating eye drops, dry-eye relief drops |
| Sodium chloride | 2% to 5% | Hypertonicity eye drops, corneal-swelling relief product |
| Naphazoline hydrochloride | 0.01% to 0.03% | Redness-relief eye drops, eye-decongestant drops |
| Tetrahydrozoline hydrochloride | 0.01% to 0.05% | Redness-relief eye drops, eye-decongestant drops |
| Phenylephrine hydrochloride | 0.08% to 0.2% | Redness-relief eye drops, ophthalmic vasoconstrictor |
| Zinc sulfate | 0.25% | Ophthalmic astringent, eye-irritation relief product |
FDA Monograph M018 includes additional active ingredients, concentration conditions, permitted combinations, dosage-form limitations, sterility requirements, and labeling requirements. This table provides a simplified overview of common ophthalmic ingredients and does not replace a review of the complete monograph.
Review ophthalmic labeling as part of the finished product’s overall compliance position. Active ingredients, concentration, intended use, dosage form, sterility, Drug Facts content, warnings, directions, container statements, principal display panel statements, and online marketing should align with the product’s applicable conditions.
Ophthalmic product claims should match the active ingredient, concentration, intended use, and finished dosage form. Depending on the applicable monograph condition, products may be marketed to relieve dryness and irritation, temporarily relieve redness of the eye, relieve discomfort from minor eye irritations, or wash the eye to remove loose foreign material.
A product should not use broader claims for treating eye infections, glaucoma, conjunctivitis, cataracts, vision correction, chronic eye disease, eye injuries, or other conditions unless those claims are supported through an appropriate regulatory pathway. Claims on packaging, ecommerce listings, retailer descriptions, websites, social media, and advertising should match the Drug Facts panel.
The Drug Facts panel should identify each active ingredient and its concentration, together with the corresponding purpose. The product name, front-label claims, and terms such as “lubricant eye drops,” “artificial tears,” “redness relief,” “eye wash,” or “ophthalmic solution” should match the product’s active ingredient and permitted intended use.
If an ophthalmic product contains more than one active ingredient, review the formulation and labeling for applicable combination conditions. Do not assume that separately permitted ophthalmic active ingredients can be combined in any concentration, dosage form, or claim combination.
Ophthalmic products generally require product-specific warning statements and directions. Depending on the active ingredient and intended use, warnings may address avoiding contamination of the container tip, not touching the tip to the eye or another surface, and stopping use and asking a doctor if eye pain, vision changes, continued redness, or irritation occurs.
Redness-relief ophthalmic products containing vasoconstrictor ingredients should include the warning: “Overuse of this product may produce increased redness of the eye.” Labels for these products may also include applicable warnings about cloudy or discolored solution.
Directions should match the active ingredient, product type, dosage form, frequency of use, and applicable age group. Use ophthalmic products only as directed, and ensure the finished product meets applicable sterility and packaging requirements.
Ophthalmic products should include appropriate Drug Facts information, including active ingredients, purpose, uses, warnings, directions, and inactive ingredients. The Drug Facts panel should correspond to the finished product that is commercially distributed.
Review product names, dry-eye claims, redness-relief claims, eye-wash claims, website content, retailer product descriptions, and advertising for consistency with the Drug Facts panel. Claims on ecommerce listings, social media, and other marketing materials should not expand the product’s permitted intended use.
This page provides a simplified overview of FDA OTC Monograph M018. It does not include every active ingredient, concentration range, permitted combination, dosage-form requirement, sterility requirement, labeling detail, warning, direction, or FDA administrative order that may apply to a specific ophthalmic product.
For complete and current requirements, including active-ingredient conditions and administrative orders applicable to OTC ophthalmic drug products, review the related official FDA monograph resource.
Ophthalmic compliance involves more than selecting an active ingredient. A product review may include active ingredients, concentration levels, intended use, dosage form, sterility, container and closure considerations, labeling claims, Drug Facts labeling, warnings, directions, manufacturing activities, and drug-listing information.
We assist with:
Need help with an FDA-regulated ophthalmic product? Our team can assist with Drug Establishment Registration, OTC Drug Listing, NDC Labeler Codes, OTC Drug Label Review, and Drug Master Files.
_______ Related Services _______
_______ Related Services _______